Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 69Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 48Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 35Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Biliary Tract Neoplasms 29Neoplasms 28Neoplasm Metastasis 28Cholangiocarcinoma 26Triple Negative Breast Neoplasms 25Pancreatic Neoplasms 25Ovarian Neoplasms 24Liver Neoplasms 18Head and Neck Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 14Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Radiotherapy 9Cisplatin 9pembrolizumab 6Methods 6fludarabine 4Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4Early Intervention, Educational 4Cyclophosphamide 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Gemcitabine 3Carboplatin 3Brachytherapy 3Bleomycin 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2lenvatinib 2entinostat 2aflibercept 2Trastuzumab 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Vulvar Neoplasms × durvalumab × Clear all
NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

M.D. Anderson Cancer Center

Phase 1 Completed
20 enrolled
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡